



# UKCTOCS: Ovarian Cancer Screening

Speaker: Prof. USHA MENON


Discussant: Dr. JUNG CHEN

Date: Jan-18<sup>th</sup>-2024



# Q1. The screening methodology: Risk of Ovarian Cancer Algorithm (ROCA)


- How does the trial define a **positive** CA-125 test?
- How to assess the “**longitudinal change**”? How many fold increase from the patient’s baseline would be considered a “positive” result?



## Q2. False positive screening cases

- Those who underwent surgeries due to positive screening results but proved **negative** for malignancy.
- What was the approximate percentage?
- What were their pathological diagnoses?


# Demographic Difference from UK to Asia



Matz M, et al., *Gynecol Oncol*, 2017 Feb; 144(2): 405-413.

# Ovarian Cancer Epidemiology: Taiwan

Percentage of Histological types of epithelial ovarian cancer in Taiwan



## Q3. Subgroup Analysis

- Is there a specific subgroup of patients the authors consider the UKCTOCS will be helpful(cancer mortality reduction)?
- What is the future of ovarian cancer screening?





台大醫院雲林分院院區  
NATIONAL TAIWAN UNIVERSITY HOSPITAL, YUN-LIN BRANCH HOSPITAL REGION